ASSERTIO THERAPEUTICS, INC. Research and Development Expense (Excluding Acquired in Process Cost)
ASSERTIO THERAPEUTICS, INC. reported Research and Development Expense (Excluding Acquired in Process Cost) of $1.04 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2020-05-11
- ASSERTIO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2020-03-31 was $1.04M, a 41.94% decline year-over-year.
- ASSERTIO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2019-03-31 was $1.79M.
- ASSERTIO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2019 was $10.11M, a 25.67% increase from fiscal 2018.
- ASSERTIO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2018 was $8.04M, a 41.38% decline from fiscal 2017.
- ASSERTIO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2017 was $13.72M.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month |
|---|---|---|
| 2020-03-31 | $1.04M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $10.11M 10-K · filed 2020-03-10 | |
| 2019-03-31 | $1.79M 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $8.04M 10-K · filed 2020-03-10 | |
| 2017-12-31 | $13.72M 10-K · filed 2020-03-10 |